{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:32:21Z","timestamp":1780468341775,"version":"3.54.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the impact of the COVID-19 pandemic lockdowns on the outcomes of eyes treated for neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion in eight countries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A multicenter international database study of 5,782 eyes (4,708 patients) receiving intravitreal antivascular endothelial growth factor injections before, during, and after national lockdowns. The baseline visit was defined as the last visit within 3 months before lockdown, and prelockdown and postlockdown periods were defined as 6 months before and after the lockdown date.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eyes with neovascular age-related macular degeneration (n = 4,649) lost vision in all countries in proportion to the reduced number of injections. The mean visual acuity change postlockdown ranged from \u22120.4 to \u22123.8 logarithm of the minimum angle of resolution letters, and the median number of injections\/visits decreased from 4\u20135\/4\u20137 to 2\u20134\/2\u20134 postlockdown. The diabetic macular edema (n = 654) and retinal vein occlusion (n = 479) eyes' mean visual acuity change ranged from \u22122.8 to +1.7 letters and \u22121.6 to +0.1 letters, and the median number of injections\/visits decreased from 2.5\u20135\/4\u20136 to 1\u20133\/2\u20134 and from 3\u20135.5\/4\u20135 to 1\u20133.5\/2\u20133.5, respectively. The 6-month dropout rates postlockdown were 20% for neovascular age-related macular degeneration, 27% for diabetic macular edema, and 28% for retinal vein occlusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This international study provides estimates of the impact of COVID-19 pandemic lockdown on intravitreal therapy and suggests that prioritizing neovascular age-related macular degeneration eyes seems appropriate.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003368","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T23:01:25Z","timestamp":1639609285000},"page":"616-627","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["INTERNATIONAL IMPACT OF THE COVID-19 PANDEMIC LOCKDOWN ON INTRAVITREAL THERAPY OUTCOMES"],"prefix":"10.1097","volume":"42","author":[{"given":"Javier","family":"Zarranz-Ventura","sequence":"first","affiliation":[{"name":"Institut Cl\u00ednic of Ophthalmology (ICOF), Hospital Cl\u00ednic, Barcelona, Spain;"},{"name":"August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Creuzot-Garcher","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Dijon University Hospital, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verbraak","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center (UMC), Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"O\u00b4Toole","sequence":"additional","affiliation":[{"name":"Mater Private Hospital, Dublin, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Invernizzi","sequence":"additional","affiliation":[{"name":"Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, Australia;"},{"name":"Eye Cl\u00ednic, Department of Biomedical and Clinical Science \u201cL. Sacco\u201d, Luigi Sacco Hospital, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Viola","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico, Milan, Italy;"},{"name":"Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Squirrel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Greenlane Clinical Centre and District Health Board, Auckland, New Zealand; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital and University of Zurich, Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Gillies","sequence":"additional","affiliation":[{"name":"Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"from the FRB International committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00417-020-04703-x","article-title":"Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic","volume":"258","author":"Korobelnik","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.oftal.2020.04.002","article-title":"Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19","volume":"95","author":"Geg\u00fandez-Fern\u00e1ndez","year":"2020","journal-title":"Arch Soc Esp Oftalmol"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s00417-020-04791-9","article-title":"What COVID-19 has taught us: lessons from around the globe","volume":"258","author":"Koh","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ophtha.2020.03.037","article-title":"Preparedness among ophthalmologists: during and beyond the COVID-19 pandemic","volume":"127","author":"Olivia Li","year":"2020","journal-title":"Ophthalmology"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjophthalmol-2020-315994","article-title":"Novel Coronavirus disease 2019 (COVID-19): the importance of recognising possible early ocular manifestation and using protective eyewear","volume":"104","author":"Li","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jcjo.2020.06.001","article-title":"National survey of Canadian retina society members on guidelines for ophthalmic care during the COVID-19 crisis: Canadian retina research network (CR2N) COVID-19 steering committee analysis","volume":"55","author":"Chaudhary","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"R8-20250607","doi-asserted-by":"crossref","DOI":"10.1111\/aos.14752","article-title":"Recommendations for ophthalmologic practice during the easing of COVID\u201019 control measures","author":"Geg\u00fandez\u2010Fern\u00e1ndez","year":"2021","journal-title":"Acta Ophthalmol."},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40942-020-00226-z","article-title":"Proposed algorithm during COVID-19 pandemic for patient management in medical retina clinic","volume":"6","author":"Corazza","year":"2020","journal-title":"Int J Retina Vitreous"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/1120672120962032","article-title":"Intravitreal injections during COVID-19 outbreak: real-world experience from an Italian tertiary referral center","volume":"31","author":"Carnevali","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.oret.2020.05.015","article-title":"Management of neovascular age-related macular degeneration during the COVID-19 pandemic","volume":"4","author":"Corradetti","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00417-020-04955-7","article-title":"Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic","volume":"258","author":"Borrelli","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1007\/s00417-020-04858-7","article-title":"Impact of COVID-19 on outpatient visits and intravitreal treatments in a referral retina unit: let's be ready for a plausible \u201crebound effect\u201d","volume":"258","author":"Borrelli","year":"2020","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/IAE.0000000000002941","article-title":"Impact of coronavirus disease pandemic on intravitreal injections treatment for macular diseases","volume":"41","author":"Viola","year":"2021","journal-title":"Retina"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2147\/OPTH.S267950","article-title":"Impact of the covid-19 pandemic on essential vitreoretinal care with three epicenters in the United States","volume":"14","author":"El Hamichi","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s42399-020-00614-4","article-title":"The impact of COVID-19 on intravitreal injection compliance","volume":"2","author":"Wasser","year":"2020","journal-title":"SN Compr Clin Med"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","article-title":"Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration","volume":"40","author":"Holz","year":"2020","journal-title":"Retina"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/eye.2016.149","article-title":"The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care","volume":"30","author":"Liew","year":"2016","journal-title":"Eye (Lond)"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.ophtha.2014.04.026","article-title":"The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes","volume":"121","author":"Zarranz-Ventura","year":"2014","journal-title":"Ophthalmology"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti\u2013VEGF drug type for 1 year in the IRIS registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","article-title":"Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration","volume":"122","author":"Arnold","year":"2015","journal-title":"Ophthalmology"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00417-020-05016-9","article-title":"Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age\u2013related macular degeneration: real world data from the Fight Retinal Blindness registry","volume":"259","author":"Figueras-Roca","year":"2021","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","article-title":"Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness project","volume":"34","author":"Gillies","year":"2014","journal-title":"Retina"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.04.012","article-title":"Defining a minimum set of standardized patient-centered outcome measures for macular degeneration","volume":"168","author":"Rodrigues","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s10792-021-01854-6","article-title":"The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol","volume":"41","author":"Sevik","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R31-20250607","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2020.576275","article-title":"Effects of the COVID-19 pandemic on anti-vascular endothelial growth factor treatment in China","volume":"7","author":"Yang","year":"2020","journal-title":"Front Med"},{"key":"R32-20250607","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4103\/ijo.IJO_2807_20","article-title":"Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown","volume":"69","author":"Sindal","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R33-20250607","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.oret.2020.06.027","article-title":"Increased number of submacular hemorrhages as a consequence of coronavirus disease 2019 lockdown","volume":"4","author":"Romano","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R34-20250607","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41433-020-01315-x","article-title":"Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence","volume":"35","author":"Teo","year":"2021","journal-title":"Eye (Lond)"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:03:16Z","timestamp":1749319396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003368"}},"subtitle":["Fight Retinal Blindness Registry"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003368","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}